DAX22.747 +0,8%Est505.578 +0,7%MSCI World4.343 -0,1%Top 10 Crypto8,8700 +3,5%Nas21.191 +1,9%Bitcoin58.105 -0,2%Euro1,1516 +0,4%Öl118,6 +3,7%Gold4.588 +1,7%

Aktion bei finanzen.net ZERO: Sichere dir jetzt 50 € Prämie + 1 Aktie + 2 ETF-Anteile gratis! Aktion bei finanzen.net ZERO: Sichere dir jetzt 50 € Prämie + 1 Aktie + 2 ETF-Anteile gratis!

Jetzt bei finanzen.net ZERO: 50 € + Aktie + ETF gratis!

Centessa Pharmaceuticals Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

34,80 EUR +10,80 EUR +45,00 %

15:46:20

STU

34,40 EUR +8,80 EUR +34,38 %

14:41:45

HAML

Centessa Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Div. Rendite0,00%

WKNA3CQ72

ISINUS1523091007

SymbolCNTA

Centessa Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

14.05.25GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

24.03.25GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

12.11.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

WerbungCentessa Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.09.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

11.09.24GlobeNewswireCentessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

10.09.24GlobeNewswireCentessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

27.08.24GlobeNewswireCentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research

13.08.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

13.05.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

24.04.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23.04.24GlobeNewswireCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

22.04.24GlobeNewswireCentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

28.03.24GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

10.12.23GlobeNewswireCentessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

13.11.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

25.10.23GlobeNewswireCentessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

14.08.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

10.07.23GlobeNewswireCentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

24.05.23GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences

22.05.23GlobeNewswireCentessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

12.05.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Centessa Pharmaceuticals News

Centessa Pharmaceuticals News: auf dieser Seite finden Sie alle Centessa Pharmaceuticals News und Nachrichten zur Centessa Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Centessa Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Centessa Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.